Immuneering Corp (IMRX) Annual Income Statement (USD)
IMRX Quarterly Financials (USD)
Frequently Asked Questions About Immuneering Corp (IMRX) Stock
Immuneering Corp's (IMRX) last reported annual revenue was USD 455.00.
Immuneering Corp's (IMRX) annual revenue growth rate based on the revenue reported in the past 5 years is : -81.97%
Immuneering Corp's(IMRX) is not profitable as of its last reported annual financials.
The net profit margin for Immuneering Corp's(IMRX) from its laster reported year is -11752004.84%
The return on equity (ROE) for Immuneering Corp's(IMRX) from its last reported annual financials is : -61.81%
The return on assets (ROA) for Immuneering Corp's(IMRX) from its last reported annual financials is : -37.42%
The return on invested capital (ROIC) for Immuneering Corp's(IMRX) from its last reported annual financials is : -58.29%
The Debt to Equity ratio for Immuneering Corp's(IMRX) from its last reported annual financials is : 0.00%
The dividend yield for Immuneering Corp's(IMRX) from its laster reported year is 0.00%
Immuneering Corp's(IMRX) has negative cash flow as of its last reported annual financials.
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for IMRX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
